NCT04060758View on ClinicalTrials.gov

Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 11, 2020

Primary Completion Date

May 13, 2025

Study Completion Date

October 31, 2025

Conditions
Open Angle Glaucoma
Interventions
DRUG

PA5108 Latanoprost FA SR Ocular Implant

Ocular Implant

Trial Locations (9)

2150

PersonalEYES, Castle Hill

3002

Centre for Eye Research Australia, East Melbourne

3040

Essendon Eye Clinic, Essendon

3065

Melbourne Eye Specialists, Fitzroy

3133

Eye Surgery Associates, Vermont South

3171

Eyes First, Springvale

3550

Bendigo Eye Clinic, Bendigo

5034

Goodwood Eye Centre, Millswood

6011

Capital Eye Specialists, Te Aro

Sponsors

Lead Sponsor

PolyActiva Pty Ltd
All Listed Sponsors
lead

PolyActiva Pty Ltd

INDUSTRY

NCT04060758 - Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma | Biotech Hunter | Biotech Hunter